IMPORTANT SAFETY INFORMATIONPRESCRIBING INFORMATION

FOLOTYN is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (R/R PTCL). This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.

We've created interactive resources to help educate you on FOLOTYN— and support your patient's treatment

Interactive Case Study

Help a fellow navigate treatment options for relapsed/refractory PTCL in this interactive case study.

FOLOTYN e-detail